The landscape of dementia prognosis has evolved radically with the advent of refined biomarkers, which include amyloid PET scans, tau imaging, and blood-based tests that will detect Alzheimer's pathology several years right before symptoms emerge. Even though these technological advances depict outstanding progress in being familiar with neurodegen